Abivax (ABVX) – Investment Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Abivax (NASDAQ: ABVX):

• 1/21/2026 – Abivax had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/9/2026 – Abivax had its price target raised by analysts at Morgan Stanley from $101.00 to $145.00. They now have an “overweight” rating on the stock.
• 1/8/2026 – Abivax was given a new $131.00 price target on by analysts at Oppenheimer Holdings, Inc..
• 1/8/2026 – Abivax had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 1/8/2026 – Abivax had its price target raised by analysts at BTIG Research from $120.00 to $150.00. They now have a “buy” rating on the stock.
• 12/18/2025 – Abivax had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $175.00 price target on the stock.
• 12/16/2025 – Abivax had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $142.00 price target on the stock.
• 12/16/2025 – Abivax had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/16/2025 – Abivax had its price target raised by analysts at Citizens Jmp from $114.00 to $131.00. They now have a “market outperform” rating on the stock.
• 12/13/2025 – Abivax was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.